

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barton, et al.

Serial No.: 10/552,571

Group Art Unit No.: 1633

Filed: 11 October 2005

Examiner: Long, Scott D.

For: Process for Improving the Manufacture of Clavams e.g. Clavulanic Acid

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents
Mail Stop: Sequence
P.O. Box 1450
Alexandria, Va 22313-1450

(X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

(X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (g) does not include new matter.


(X) I hereby state that the submission filed in accordance with 37 CFR §1.821 (h) does not include new matter or go beyond the disclosure in the international application as filed.

() I hereby state that the amendments, made in accordance with 37 CFR §1.825 (a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,


Andrea V. Lockenour
Attorney for Applicants
Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090
Avigpatappn@clavulanic.acie/pb60213seq_transmittal